News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)

Posted on

SAN ANTONIO–(MEDIA)–Following the recent start of its pediatric and adult Phase 2 clinical study for atopic dermatitis in Australia, Santalis¬†Pharmaceuticals¬†today announced it has obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate a multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for the treatment of mild to moderate atopic dermatitis (AD), also known as eczema. Read More Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)